ADXN — Addex Therapeutics Balance Sheet
0.000.00%
- CH₣4.96m
- CH₣1.65m
- CH₣1.65m
Annual balance sheet for Addex Therapeutics, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Cash and Short Term Investments | 31.5 | 18.7 | 20.5 | 6.96 | 3.87 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.118 | 0.068 | 0.324 | 0.598 | 0.151 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 32.4 | 19.5 | 21.9 | 7.83 | 4.23 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.571 | 0.633 | 0.542 | 0.399 | 0.353 |
Other Long Term Assets | |||||
Total Assets | 33 | 20.2 | 22.5 | 8.28 | 4.64 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 5.68 | 3.62 | 4.13 | 3.28 | 2.89 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 7.5 | 5.57 | 5.61 | 3.37 | 3.5 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 25.5 | 14.6 | 16.9 | 4.91 | 1.15 |
Total Liabilities & Shareholders' Equity | 33 | 20.2 | 22.5 | 8.28 | 4.64 |
Total Common Shares Outstanding |